Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Time to Sell?

by · The Cerbat Gem

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $53.55, but opened at $46.64. Nanobiotix shares last traded at $48.0850, with a volume of 37,689 shares.

Analyst Ratings Changes

NBTX has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Tuesday, April 21st. TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. UBS Group lifted their price target on Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Finally, Guggenheim lifted their price target on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.67.

Get Our Latest Report on Nanobiotix

Nanobiotix Trading Up 5.8%

The stock’s 50-day moving average is $34.24 and its 200 day moving average is $26.31.

Nanobiotix (NASDAQ:NBTX – Get Free Report) last released its earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $3.42 million for the quarter. As a group, equities analysts anticipate that Nanobiotix S.A. – Sponsored ADR will post 0.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Nanobiotix

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC acquired a new stake in shares of Nanobiotix during the 4th quarter valued at about $390,000. Marshall Wace LLP bought a new stake in shares of Nanobiotix in the 4th quarter valued at approximately $220,000. Royal Bank of Canada grew its stake in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares in the last quarter. Finally, Optiver Holding B.V. bought a new stake in shares of Nanobiotix in the 3rd quarter valued at approximately $101,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

(Get Free Report)

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.

See Also